PRG-1 relieves pain and depressive-like behaviors in rats of bone cancer pain by regulation of dendritic spine in hippocampus

Xingfeng Liu1,2, Zhuo Xie3, Site Li3, Jingxin He3, Song Cao4, Zhi Xiao1,2✉
1. Guizhou Key Laboratory of Brain Science, Zunyi Medical University, Zunyi 563000, China.
2. Guizhou Key Laboratory of Anesthesia and Organ Protection, Zunyi Medical University, Zunyi 563000, China.
3. Graduate School, Zunyi Medical University, Zunyi 563000, China.
4. Department of Pain Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi, 563000, China.
✉ Corresponding author: Zhi Xiao, Zunyi Medical University, Xuefu West Road 6, Xinpu District, Zunyi 563000, China. Phone: +86 (0) 851 2864 0039; E-mail: zhixiao@zmu.edu.cn.
© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/).
See http://ivyspring.com/terms for full terms and conditions.

Received: 2021.02.15; Accepted: 2021.09.06; Published: 2021.09.21

Abstract

Rationale: Pain and depression, which tend to occur simultaneously and share some common neural circuits and neurotransmitters, are highly prevalent complication in patients with advanced cancer. Exploring the underlying mechanisms is the cornerstone to prevent the comorbidity of chronic pain and depression in cancer patients. Plasticity-related gene 1 (PRG-1) protein regulates synaptic plasticity and brain functional reorganization during neuronal development or after cerebral lesion. Purinergic P2X7 receptor has been proposed as a therapeutic target for various pain and neurological disorders like depression in rodents. In this study, we investigated the roles of PRG-1 in the hippocampus in the comorbidity of pain and depressive-like behaviors in rats with bone cancer pain (BCP).

Methods: The bone cancer pain rat model was established by intra-tibial cell inoculation of SHZ-88 mammary gland carcinoma cells. The animal pain behaviors were assessed by measuring the thermal withdrawal latency values by using radiant heat stimulation and mechanical withdrawal threshold by using electronic von Frey anesthesiometer, and depressive-like behavior was assessed by sucrose preference test and forced swim test. Alterations in the expression levels of PRG-1 and P2X7 receptor in hippocampus were separately detected by using western blot, immunofluorescence and immunohistochemistry analysis. The effects of intra-hippocampal injection of FTY720 (a PRG-1/PP2A interaction activator), PRG-1 overexpression or intra-hippocampal injection of A438079 (a selective competitive P2X7 receptor antagonist) were also observed.

Results: Carcinoma intra-tibia injection caused thermal hyperalgesia, mechanical allodynia and depressive-like behaviors in rats, and also induced the deactivation of neurons and dendritic spine structural anomalies in the hippocampus. Western blot, immunofluorescence and immunohistochemistry analysis showed an increased expression of PRG-1 and P2X7 receptor in the hippocampus of BCP rats. Intra-hippocampal injection of FTY720 or A438079 attenuated both pain and depressive-like behaviors. Furthermore, overexpression of PRG-1 in hippocampus has similar analgesic efficacy to FTY720. In addition, they rescued neuron deactivation and dendritic spine anomalies.

Conclusion: The results suggest that both PRG-1 and P2X7 receptor in the hippocampus play important roles in the development of pain and depressive-like behaviors in bone cancer condition in rats by dendritic spine regulation via P2X7R/PRG-1/PP2A pathway.

Key words: bone cancer pain, PRG-1, P2X7 receptor, depression, dendritic spine

Introduction

Recent advances in cancer diagnosis and treatments mean that 50% cancer patients can expect to survive the disease for 10 or more years [1], whereas depression, a feeling of hopelessness,
anhedonia, decreased cognitive function and impaired everyday activity are common to terminal patients with cancer, and cancer related chronic pain deteriorates depression-like behaviors [2]. Meanwhile, pain and depression are two common complications of advanced cancer, but often had an insufficient emphasis, influencing quality of life, treatment compliance, and cancer survival [3, 4]. Depression affects up to 20% of patients with cancer, compared with the figure of 5% for prevalence in the general population in 2017 [5]. Thus, the management of pain in patients with cancer is a challenge and exploring the mechanisms underlying the comorbidity of chronic pain and depression in cancer patients is the foundation for pain and depression comorbidity control.

Around 30–50% cancers, particularly malignant metastases in bone, and almost all patients with advanced cancer, will experience persistent pain during the course of their disease, and pain intensity appears to increase as cancer progresses [6-9]. Local factors including direct damage to sensory nerve fibres, infiltration of nerve roots by cancer cells and algogenic biological agents within the micro-environment of the tumor bring about central sensitization of dorsal horn neurons, characterized by neurochemical reorganization with persistent cancer pain [6, 8, 10-12]. After integration and modulation at the spinal level, the enhanced pain messages are transmitted to the brain, where the final pain experience is generated [13]. Finally, pain alters function and activity in the descending controls, which relay information from higher brain centers via the midbrain and brainstem to the spinal cord, ongoing and evoked pain and comorbidities [13, 14]. The persistent barrage of neural signals delivered by primary nociceptors induces structural and functional changes in the dorsal horn of the spinal cord, and this neural plasticity facilitates the development of persistent central sensitization, and consequently promotes bone cancer pain (BCP) [10], but the underlying mechanism is still not clear.

The hippocampus is one of the key brain regions in pain signals modulating [15], particularly with respect to the affective aspect of pain perception [16, 17] and abnormal emotional processes, including anxiety and depression [18]. Accumulating studies have suggested that chronic pain arising from peripheral nerve injury induces alterations in different areas of the brain including impaired hippocampal mossy fiber-CA3 synaptic plasticity and DG neurogenesis [19-21]. The hippocampus functional connectivity networks were disturbed under chronic pain condition by an fRMI study [22, 23]. In addition, many studies found that neuropathic pain rats exhibited structural and functional alterations in the hippocampus after peripheral nerve injury [24, 25], including hippocampal glutamatergic synapses loss [26]. Studies on chronic pain in patients and animal models have shown hippocampal volume loss [27], interfered synaptic plasticity and neurogenesis [15, 24, 28, 29]. Consistent with these, several experimental studies have found that direct hippocampal manipulation alters nociceptive behavior. Activation of the dorsal hippocampus reverses neuropathic pain through local excitatory and opioidergic mechanisms affecting dorsal hippocampus functional connectivity [30]. Direct injection of the local anesthetic like lidocaine to the dentate gyrus (DG) region of the hippocampus produces analgesia [31]. Neuropathic pain induced-depressive-like symptoms and hippocampal plasticity are dependent on hippocampal TNFR1 (tumor necrosis factor receptor 1) signaling. TNFR1(-/-) mice did not change hippocampal neurogenesis and plasticity after injury nor develop depressive-like symptoms [29]. However, the underlying mechanism of hippocampus regulation of pain or depression is still not clear. Therefore, it is necessary to explore the hippocampal cellular and molecular changes during chronic pain conditions.

Plasticity-related gene 1 (PRG-1) is the prototype of the family of plasticity-related genes (PRGs) which are called lipid phosphate phosphatase (LPP)-related proteins (LPPRs) according to nomenclature rules based on their structural similarity to the LPP family members [32], also termed LPPR-4 [33]. Hippocampal PRG-1 plays an important role in the maintenance of synaptic homeostasis by modulating glutamatergic junction [34] and intracellular protein phosphatase 2A (PP2A)/β1-Integrin signaling [35]. The glutamatergic junction signaling pathway involves lysophosphatidic acid (LPA) via presynaptic LPA2 receptors and PRG-1 from the postsynaptic side [34]. Deletion of PRG-1 in mice leads to epileptic seizures and augmentation of excitatory postsynaptic currents (EPSCs), which further confirmed the important role of PRG-1 in modulation of hippocampal excitability [34]. The PRG-1 intracellular PP2A/β1-Integrin signaling could affect synaptic plasticity and memory formation via interaction of its cytoplasmic calmodulin-binding domain (CBD) [35, 36]. The numbers of the spine in hippocampal CA1 sr, CA1 so, and moDG regions revealed significantly lower densities in PRG-1-deficient mice compared with wild type (WT) littermate controls on P12, P19 in mice [35]. In study on human tissue, PRG-1 was found differentially regulated in the substantia nigra of clinically and histologically confirmed epileptic seizures and Parkinson’ s disease patients [37]. At present, studies
on PRGs family mainly focus on neuropsychiatric diseases and nerve injuries such as epilepsy [34, 38, 39], schizophrenia [40, 41], memory disorders [35], nerve trauma [42, 43], sensory discrimination deficit [44, 45], etc. Besides, PRG-1 may be involved in cancerogenesis because the target role of LPA in cancer [33, 46]. However, whether PRG-1 or PRGs family play a role in pain or depressive-like behaviors has not been investigated.

P2X7 receptor, a kind of adenosine triphosphate (ATP) ligand gated ion channel receptor subtype, was a research spotlight in recent years due to the particularity of its molecular structure. P2X7Rs have been proposed as therapeutic targets for various inflammation, pain, tumor and neurological disorders [47-51] as well as for autism and depression-like behavior in mice [52, 53]. The activation of spinal and supraspinal P2X7 receptors plays a key role in the occurrence and development mechanisms of various kinds of acute or chronic pain [54-56], including neuropathic pain and inflammatory pain [49], while the exact role of P2X7 receptor in BCP still remains controversial. The activation of P2X7 receptor is involved in development process of BCP by the mechanism of descending facilitatory by Huang et al. [57]. While P2X7 receptor plays an analgesic effect on BCP by Hansen et al. [58] and Li et al. [54]. In the tumor microenvironment, ATP is released to form a local high concentration ATP environment, which activates P2X7 receptors and causing the influx of Ca2+ in cells [59]. Repeatedly relatively high concentrations of ATP stimulate the formation of membrane pore depended on P2X7 receptor, which is closely related to the formation of mechanical touch induced pain in mice, arthritis, and pain in patients after mastectomy [60]. Large numbers of Ca2+ influx activate a variety of downstream cell signal transduction pathways that excite nociceptive neurons, thereby increasing their excitability and resulting in pain sensation [59, 61, 62]. Rett syndrome (RTT), an early-onset neurodevelopmental disorder, resulted in accumulation of P2X7R-expressing monocytes and macrophages located at the edge of the cerebral cortex, while P2X7R deficiency or pharmacological block restored cortical dendritic spine plasticity, and ameliorated social behavioral defects of RTT mice [63].

In this study, for the first time, we found that hippocampal PRG-1 activation is involved in the regulation of BCP, and there is partial co-localization of hippocampal PRG-1 and P2X7 receptors, which suggested there existed a brand new pain modulation signaling pathway. Additionally, we identified that PRG-1 is involved in BCP and depressive-like behaviors by regulating dendritic spine development in hippocampus via P2X7R/PRG-1/PP2A signaling. Based on the results of this study, a new pathway modulating BCP was explored, which is helpful to expand a novel analgesia and depression relief strategies targeting PRG-1.

Methods

Animals

Pathogen-free, female Sprague–Dawley rats weighing 210±10 g (n = 162) were purchased from the Tianjin Biotechnology Co. Ltd. (license number: SCXK (xiang) 2019-0014; Changsha, China) and used for all experiments. Rats were housed in a temperature (23 ± 2 °C) and humidity (55 ± 5%) -controlled environment, with a 12-h light/dark cycle (8:00 a.m. - 8:00 p.m.) and free access to food and water. All experimental procedures were in accordance with the guidelines of the Ethical Committee of the International Association for the Study of Pain [64] and ethically approved by the Animal Care Ethics Committee of Zunyi Medical University. Try to minimize the number of animals used and reduce their suffering from experimental procedures.

There were 54 rats in the first part of the experiment: normal group (n = 18), sham group (n = 18) and BCP group (n = 18) for behaviors test, and 6 rats in each group were used for western blots and RT-PCR. 6 rats in each group were used for Golgi staining and the rest 6 rats were used for nissl staining and immunofluorescence. There were 48 rats in the second part of the experiment: BCP +FTY720 group (n = 18), BCP +A438079 group (n = 18), BCP +BzATP group (n = 6) and BCP +Okadaic Acid (OA) group (n = 6). There were 60 rats in the third part of the experiment: BCP +PRG-1 overexpression (OE) group (n = 12), BCP +PRG-1 knock down (KD) group (n = 12), BCP +P2X7R KD group (n = 12), BCP +PRG-1 OE +BzATP group (n = 6), BCP +PRG-1 KD + FTY720 group (n = 6), BCP +PRG-1 KD +A438079 group (n = 6), and BCP +P2X7R KD+ FTY720 group (n = 6). Cutaneous sensitivity to thermal and mechanical stimulation was measured before surgery and every 5-7 days after surgery for 6 weeks. Sucrose preference test was examined every week and forced swim test was performed on postoperative day 20. BCP Rats without depression-like behavior were not included in the statistics. On postoperative day 45, all rats were killed and the hippocampus was harvested for further analyses.

Animal model of bone cancer pain

All rats were assessed for their baseline thresholds to mechanical and thermal stimuli before surgery. Only the rats with normal baseline responses
were used.

BCP model was established as described previously [65]. In brief, the rats were anesthetized with pentobarbital sodium (50 mg/kg body weight, intraperitoneal, i.p.), followed by a 1.5-cm incision on the right leg of the rat to expose the tibia. 20 μL of SHZ-88 carcinoma cells (10^7 cells/mL), purchased commercially from the Shanghai Cell Bank of the Chinese Academy of Sciences (Shanghai, China), was slowly injected into the intramedullary cavity of the right tibia. The injection site was immediately sealed with sterile bone wax, and the incision wound was treated with penicillin and layered sutured. The sham group was injected with boiled cells (20 min/95 °C) instead. The day of carcinoma cells inoculation is day 0.

Bone radiological detection

Tibia radiological detection was performed on day 28 after intra-tibia injection of SHZ-88 to determine bone destruction. After anesthesia with pentobarbital sodium (50 mg/kg body weight, i.p.), the right hind limb of rats was irradiated with an intraoral X-ray source under the condition of 0.32 s at 60 kV, 7 mA (Kodak, 2100, Carestream Health, Inc.). And the radiographs of contralateral tibia were taken as control.

Hematoxylin-eosin (HE) staining

Histological staining was assayed as described [66] with little modification. Rat tibia was separated, rinsed in normal saline, and fixed in 4% paraformaldehyde (PFA) overnight, followed by decalcification in EDTA decalcifying solution (Solarbio) in 4 °C for 2 weeks until easily penetrated through by a needle. Dehydration, transparency and paraffin embedding were operated as standard protocols. 5 μm sections were sliced using paraffin microtome (Leica RM2235, Germany) and pasted on gelatin slides. The sections were stained with hematoxylin and eosin staining kit (Beyotime) according to the manufacturer’s protocol. The mounted slides were observed under light microscope (Leica, Germany).

Implantation of hippocampal cannula and microinjection procedures

After anesthesia with pentobarbital sodium (50 mg/kg body weight, i.p.), the rats were placed on a stereotaxic frame (RWD Life Science, China). The surface of skull was exposed. The virus expression vector LV-Plppr4, LV-Plppr4-RNAi or LV-P2X7R-RNAi (genechem, Shanghai) was slowly injected (200 nl/min) bilaterally into the hippocampus area through a fine glass pipette by microsyringe pump (RWD Life Science, China) a week before BCP operation. The pipette remained in place for 10 min to ensure complete diffusion of the virus and then slowly removed [67]. The stereotaxic coordinates of hippocampus were AP = -3.72 mm, ML = ±2.0 mm, and DV = -3.0 mm, according to the rat brain atlas [68].

For drug treatment experiments, a guide cannula [0.48 mm outside diameter (O.D.); 0.34 mm inner diameter (I.D.)] was implanted into the hippocampus and fixed to the skull of rats. For micro-injection, rats were inserted with an injection cannula (0.3 mm O.D.; 0.5 mm longer than the guide cannula) into the guide cannula. A total volume of 0.5 μL was slowly injected, and the injector kept in place for 10 min to allow complete diffusion of the drug before slowly withdrawn. Microinjection sites were checked by histological examination [54].

Behavioral assessment

Inclined plane test

The functional deficit of motor, including muscular strength and proprioception, was quantitated using an inclined plane as reported by Rivlin et al. [69]. The rats were placed crosswise on an inclined plane which can be adjusted to provide a slope of varying grade. The initial angle of the inclined plane was 25, and the angle was increased slowly by 5 degrees. The maximum angle of the plane at which the rats can maintain its position for 5 s without falling was recorded. The average values from the measurements of five times for each rat were defined as the inclined plane degree [54].

Radiant heat test

Thermal hyperalgesia was tested in rats as reported by Hargreaves et al. [70] previously to evaluate thermal withdrawal latency (TWL). Each rat was placed in an individual Plexiglass house, allowed to acclimate for 30 min until they settled down. 52 ± 0.2 °C radiant heat (50 W, 8 V bulb) was applied to the plantar surface of the hind paw with the plantar radiant heat instrument (IITC Life Science Instruments, USA). The latency period was recorded until the removal of the paw (including lifting, licking, flicking, shook or jumping). The cut-off limit was set to 60 s. Each hind paw was measured for five times at 5-min intervals [54].

The electronic von Frey meter test

Electronic pressure meter test described by Vivancos GG et al. [71] was carried out to evaluate mechanical withdrawal threshold (MWT). Each rat was placed in an individual plastic chamber for 30 min until they calm down. Mechanical allodynia of rat hind paw was measured with the electronic von
Frey anesthesiometer (IITC Life Science Instruments, USA). The polypropylene tip was applied to the plantar surface of the hind paw with a gradual increase in pressure until a functional response (including lifting, licking, flicking, shook or jumping). The threshold pressure was recorded. Each hind paw was measured for five times at 5-min intervals.

**Sucrose preference test**
Rats were trained to the presence of 2 identical drinking bottles, 1 containing 1% (w/v) sucrose solution and the other containing pure water before the experiment. After 24-h water deprivation, the rat was fed in a solitary cage, given a bottle of 1% (w/v) sucrose solution and a bottle of pure water for 3h. The position of the two bottles was swapped every 30 min to avoid position preference. The volume of sucrose solution and pure water intake were measured. The ratio of sucrose solution intake to the total liquid intake was calculated as sucrose preference (%). The decrease in sucrose preference (%) indicates an anhedonia for rats, which is a manifestation of depressive-like behavior [4].

**Forced swim test**
On the first day, rats were placed in a transparent cylindrical acrylic container (a height of 60 cm and a diameter of 20 cm) filled with tap water (22-24 °C, water height 45 cm) for 15 min swimming acclimation. On the second day, rats were forced to swim for 6 min under the same conditions. The whole experiment was recorded with a camera. The immobility time of the hind limbs was counted in the last 4 minutes. Increased ratio of immobility time was used to assess despair and hopeless behavior of the rats.

**Perfusion, immunohistochemistry and immunofluorescence**
Rats were deeply anesthetized with pentobarbital sodium (50 mg/kg body weight, i.p.) for the perfusion of normal saline (NS) through the left ventricle followed by 4% PFA. The brains were harvested, post-fixed in 4% PFA for 4-6 h at 4 °C, and cryoprotected in 30% sucrose at 4 °C until they sank. The brains were coronally cut at a thickness of 30 μm on a cryostat (Leica CM 1950, Germany).

**Co-immunoprecipitation (CoIP) and western blot (WB)**
The whole hippocampus was dissected and mechanically homogenized, then lysed in appropriate volume of radioimmunoprecipitation assay (RIPA) lysis buffer (Beyotime, China) containing phenylmethanesulfonyl fluoride (PMSF) (YEASEN) for 1 h on ice, and cleared by centrifugation for 10 min at 15000 g at 4 °C. Protein concentrations of the lysate were determined using Bradford reagent (Bio-Rad, Hercules, CA, USA).

**For co-immunoprecipitation**, the lysate was pre-cleared with agarose slurry, and incubated with PRG-1 antibody (1:100, synaptic system), then pulled down by Protein G agarose resin (absin). Finally, beads were suspended with appropriate amount of lysis buffer and analyzed by western blot.

**For western blot**, tissue lysates or immunoprecipitated samples were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto polyvinylidene fluoride (PVDF) membrane (Biosharp). Then membranes were incubated with first antibodies, including PRG-1 (1:3000, synaptic system), P2X7R (1:1000, abcam), PPP2R2A (1:1000, Cell Signaling), β-actin (1:5000, MP Biomedicals), and horseradish peroxidase (HRPO)-conjugated secondary antibodies (1:5000, dianova). Finally, membranes were developed by ECL (EpiZyme scientific).

**Nissl staining**
Nissl staining was used for the staining of nissl body in the cytoplasm of neurons. The frozen section was washed with distilled water after 4% PFA fixing for 20 min. The sections were then stained with nissl staining solution (Beyotime) for 3-10 min according to the dyeing results and requirements. The sections were washed twice with distilled water and then 70% ethanol. Finally, the changes of nissl bodies were observed under a microscope [72]. For quantification, clear and intact neural cells with nissl bodies uniformly distributed around the nuclei in the hippocampal CA1 and DG regions were counted in a blinded manner. Then the percentage of nissl positive neurons to the total number of neurons was calculated [73].

**Golgi-Cox staining and dendritic synapse quantification**
Golgi staining was used to examine synaptic plasticity. After anesthesia (50 mg/kg body weight, i.p.), the brains of rats were removed and immediately stained by Hito Golgi-Cox OptimStain™ Kit (Hito-
bic, according to the manufacturer's protocol and then photographed under a light microscope. Spines were defined as dendritic protrusions and were manually counted along a selected dendritic segment using ImageJ 6.0 software (NIH, USA) [74, 75]. In brain sections we focus our analyses on dendrites of three areas: (1) the middle molecular layer of dentate gyrus (moDG) granule cells; (2) stratum radiatum (sr, apical dendrites) and (3) stratum oriens (so, basal dendrites) of pyramidal neurons of the CA1 region. For each group around 1000 spines or at least 1000 µm dendritic length were measured. For each group, the density of dendritic spines, that is, the number of spines per µm dendrite was calculated [35]. Analysis was performed in a blinded manner.

**RNA extraction and quantitative reverse-transcription polymerase chain reaction (qRT-PCR)**

The entire hippocampus was collected and RNA was extracted using TRIzol and reverse-transcribed into cDNA using the PrimeScript™ RT reagent Kit (Takara, Japan). The differential expression of each gene was analyzed following polymerase chain reaction (PCR) using the TB Green® Premix Ex Taq™ II (Takara). The relative expression was defined as $F=2^{-\Delta\Delta CT}$. The primers were synthesized by Sangon (Shanghai, China) and listed in Table 1.

**Table 1. Primer sequences for qRT-PCR**

| Genes   | Forward                   | Reverse                |
|---------|---------------------------|------------------------|
| PRG-1   | CCGATTCAGTTGCTATGACAGG    | GGTCGATCCCGAAACAAATGTC |
| P2X7R   | CCCATGCTATTTGCTGTTGG      | CTGGTAGTTGAGACGGGAGGC  |
| Actin   | CCCCATTGAACACGGCATTAT     | GCCACGCTCGGTGAGGATTTT |

**Statistical analysis**

Data were processed with the GraphPad Prism (version 8.0.2; GraphPad Software, Inc., USA). All results are expressed as the mean ± SEM (standard error of mean) if not indicated otherwise. Data statistical analysis was done using two-tailed unpaired student t-test for comparing two groups with normal distributed data or a Mann-Whitney-U test for comparing two groups containing nonparametric distributed data. Data normalized to control values (rendering control values as 1) were calculated using a one-sample t test. One-way ANOVA with Bonferroni correction for multiple comparing groups containing normal distributed data or a Kruskal-Wallis test with a Dunn’s multiple comparisons test for multiple comparison of groups containing nonparametric distributed data. Normal distribution was assessed using the Kolmogorov-Smirnov-Test. Statistical significance was determined with an overall significance level of $p<0.05$ (n.s. for $p>0.05$, *$p<0.05$, **$p<0.01$, ***$p<0.001$).

**Results**

**Evaluation of bone destruction in BCP model**

The BCP model was validated using radiological imaging and histological analysis. On day 28, X-ray picture of the rat tibia inoculated with SHZ-88 cells (BCP) showed discontinuity of the bone structure (Figure 1A), indicating bone destruction around the cancer cell injection site. After dissection, the surface of the BCP operation tibia was discontinuous and swelled up compared with the contralateral side (uninjured rat tibia) (Figure 1B). Hematoxylin-eosin staining of tibia sections showed marked infiltrating osteolytic lesions of tibia was detected in the proximal metaphysis and cavum medullare, such as tumor cells filling in the bone marrow cavity, bone destruction along the surfaces of trabecular, invasion and thinning of cortical bone, indicating the development of bone cancer in the tibia (Figure 1C). The deficits in the bone structure were insignificant on contralateral side tibia of BCP rats or in sham rats.

**Alterations of pain threshold values and depressive-like behaviors by cancer cell inoculation**

Inclined plane test indicated that experimental procedures, such as BCP modeling operation, microinjection of virus or drugs didn’t impair motor function of rats (1-way ANOVA, $P>0.05$; Figure 1D). The TWL and MWT on the ipsilateral side of the cancer cell inoculation, which was measured before BCP operation (day 0) and at days 6, 11, 17, 20, 24, 27, 33, 39 and 44 post-operation, was significantly decreased in BCP rats but not in sham rats from postoperative day 20 to 44 (1-way ANOVA, $P<0.05$ compared with sham group at the same time point, Figure 1E-1F), suggesting that thermal hyperalgesia and mechanical allodynia was developed in rats with BCP operation. In the forced swim test, BCP rats spent significantly longer time immobile than the sham rats did from postoperative day 20 to 44 (1-way ANOVA, $P<0.05$; Figure 1G). Moreover, BCP rats showed a decreased sucrose preference than sham rats from POD 20 (1-way ANOVA, $P<0.001$; Figure 1H). Overall, the above results suggested that BCP rats displayed clear comorbidity of bone cancer pain and depression.

**Hippocampal PRG-1 and P2X7 receptor are involved in bone cancer pain**

The expression levels of PRG-1 and P2X7 receptor in the hippocampus were both increased on postoperative day 45 in the BCP rats by immunofluorescence and western blot (Figure 2A-E),
indicating activation of hippocampal PRG-1 and P2X7 receptor may be involved in bone cancer induced pain and depression. Furthermore, their subcellular distribution was studied by fluorescence microscopy, revealing partial colocalization between P2X7 receptor and PRG-1 (Figure 2B), suggesting a possible correlation of them. Meanwhile, transcripts for PRG-1 and P2X7 receptor were revealed in isolated hippocampus by qRT-PCR. Quantitative analysis showed that the transcriptions of PRG-1 and P2X7 receptor mRNA were not increased in the hippocampus of BCP rats (Figure 2F-G). These data suggested that the expression of PRG-1 and P2X7 receptor protein was specifically increased by translation, but not transcription step, in the BCP rats.

**BCP rats showed neuron deactivation and synaptic depression in the hippocampus**

Since it has been proved that PRG-1 plays a critical role in synaptic plasticity [35], we next investigated the activation of neuron and dendritic spine in the hippocampus. The nissl staining, a method to examine histological change, was performed on the hippocampus. It was found that the hippocampus has normal histology in sham group, showing abundant nissl bodies in the cytoplas of nerve cells and normal nucleoli in CA1 and DG in hippocampus. However, in the BCP hippocampus, degenerated nerve cells were found as indicated by the disappearance of nissl bodies and loss of nucleoli 45 days after BCP (Figure 3A-B). In CA1 and DG regions, the percent of nissl positive cell in the BCP group was lower than that in the sham group (Figure 3C). These data indicated that deactivation of neuron in the hippocampus was specifically induced in the BCP rats and may be related to the development of pain and depressive-like behavior in these rats.

**Figure 1.** Intra-tibia injection with SHZ-88 cells in SD rats caused bone destruction, thermal hyperalgesia, mechanical allodynia and depression-like behaviors. (A) Photo of surface of dissected tibia of BCP operation (the rat tibia inoculated with SHZ-88 cells) and contralateral side on the postoperative day 28. (B) Radiograph of the cancer cell inoculation tibia and contralateral side in BCP rats. (C) Histopathological images of tibia sections stained by hematoxylin–eosin indicate obvious infiltrating osteolytic lesions of tibia. (D) Inclined plane test indicated that BCP, virus or drug microinjection didn’t impair motor function of rats. n = 6; one-way ANOVA, P > 0.05 among all groups. (E) The BCP rats showed significant decrease in TWL and produced thermal hyperalgesia on the operation-side hind paw from postoperative day 20 to 44. n = 12; one-way ANOVA, 36: versus sham group at the same time point. (F) The BCP rats showed significant decrease in MWT and produced mechanical allodynia on the operation-side hind paw from postoperative day 20 to 44. one-way ANOVA, 36: versus sham group at the same time point. (G) BCP rats showed prolonged immobility time in FST on postoperative day 20. n = 12; one-way ANOVA, 36: versus sham group. (H) BCP group decreased sucrose preference on the sucrose preference test on postoperative day 20 compared with sham group. n = 12; one-way ANOVA, 36: versus sham group. The data are expressed as the mean ± SEM; 36P < 0.05, 36P < 0.01 and 36P < 0.001. BCP, bone cancer pain; TWL, thermal withdrawal latency; MWT, mechanical withdrawal threshold; FST, forced swimming test.
To address the role of spine plasticity in bone cancer induced pain, we compared spine densities of sham and BCP groups on 45 days after operation *in vivo* by Golgi-Cox staining. Indeed, BCP group showed a significant reduction in spine density of about 30%-50% in hippocampus (CA1 sr, CA1 so and moDG regions) (Figure 3D-H), indicating a crucial role of spine density regulation by PRG-1 in bone cancer induced pain and depressive-like behavior in these rats.
PRG-1 activation attenuated pain and depressive-like behaviors in BCP rats via PRG-1/PP2A signaling

To test for the role of hippocampal PRG-1 and P2X7 receptor in bone cancer pain, the virus vector LV-Plppr4 (PRG-1 overexpression), LV-Plppr4-RNAi (PRG-1 knock down) or LV-P2X7R-RNAi (P2X7 receptor knock down) was slowly injected unilaterally into the hippocampus area one week before BCP operation (Figure 4A). PRG-1 overexpression has a role in alleviating pain, including thermal hyperalgesia and mechanical allodynia, and depression-like behavior, while PRG-1 KD leads to an early occurred and intensified pain and depression (Figure 4B-D), indicating the analgesic and antidepressant effect of PRG-1. P2X7 receptor KD also showed an analgesic effect in BCP rats, but not a
depression-like behavior (Figure 4B-D), suggesting the algogenic effect of hippocampal P2X7 receptor.

PRG-1 regulates synaptic plasticity via intracellular PRG-1/PP2A signaling pathway [35]. To test for the role of PRG-1/PP2A signaling in mediating PRG-1-dependent bone cancer induced pain, we performed hippocampal microinjection of FTY720 (D39-43, 20 μg once per day), which serves as an activator of PP2A [76] and PRG-1/PP2A signaling [35], and BCP rats showed a significant increase in TWL and MWT with cumulative effect (Figure 4E-G) and also rescued sucrose preference of BCP rats (Figure 4H). In line with these results, selective inhibition of PP2A by okadaic acid (OA) [77] (D39-43, 100 nM, once per day) significantly decreased this TWL and MWT (Figure 4E-G). These data suggested that PRG-1/PP2A pathway attenuated bone cancer pain and depression-like behaviors in cancer-bearing rats. In contrast, selective inhibition of P2X7 receptor by antagonist A438079 (D39-43, 1 μg once per day) [78] also significantly increased TWL and MWT values without cumulative effect (Figure 4E-G). Moreover, A438079 were able to rescue sucrose preference of BCP rats (Figures 4H). In line with these results, selective enhancer of P2X7 receptor by BzATP [79] (D39-43, 100 nM once per day) significantly decreased this TWL (Figure 4E-F). These further verified the analgesic and antidepressant effect of PRG-1/PP2A pathway and the algogenic effect of hippocampal P2X7 receptor.

**PRG-1 rescued neuron deactivation and synaptic depression in the hippocampus of BCP rats**

The recovery of nerve cell morphology was observed in FTY720 treated group and PRG-1 overexpression group. We observed the re-appearance of nissl bodies and nucleoli in CA1 and DG regions (Figure 5A-B), indicating FTY720 promoted nerve regeneration as documented by nissl staining. Consistent with these results, BCP

---

**Figure 5.** PRG-1 attenuated neuron deactivation and synaptic depression in the hippocampus induced by BCP. (A) Nissl staining in CA1, DG districts of rats' hippocampus under FTY720 or A438079 treatment. (B) The graph shows the percent of nissl positive cell. n = 6; one-way ANOVA, *: versus Sham group. (C) Images of Golgi-Cox staining and (D-F) quantitative analysis showed that the spine density depression induced by BCP was reversed by FTY720. (D, n =20 Sham, 12 BCP, 14 BCP+FTY720 and 13 BCP+A438079, one-way ANOVA; E, n = 20 Sham, 11 BCP, 12 BCP+FTY720 and 12 BCP+A438079, one-way ANOVA; F, n = 12 Sham, 10 BCP, 15 BCP+FTY720 and 15 BCP+A438079, Kruskal-Wallis test; n = represents analyzed dendritic segments; *: versus Sham group; #: versus BCP group); stratum radiatum (sr, apical dendrites) and stratum oriens (so, basal dendrites) of the CA1 region, and the stratum moleculare of the dentate gyrus (moDG). (G) PRG-1 OE and P2X7R KD rescued nissl bodies and nucleoli in CA1 and DG regions. The data are expressed as the mean ± SEM; *P<0.05, **P<0.01, ***P<0.001, BCP, bone cancer pain; OE, overexpression; KD, knock down.
hippocampal microinjection of FTY720 showed an increase in spine density compared with untreated BCP rats in hippocampus CA1 (sr and so) and moDG regions (Figures 5C-F), further supporting specific PRG-1/PP2A interaction in spine formation and density induced by BCP. Meanwhile, treatment exclusive with A438079 enhanced nissl bodies and spine density in CA1 and moDG regions in BCP rats (Figures 5A-F). Furthermore, PRG-1 OE and P2X7R KD also rescued nissl bodies and nucleoli in CA1 and DG regions (Figure 5G-H). These indicated PRG-1 and PRG-1/PP2A pathway may play analgesic and antidepressant role by rescuing neuron deactivation and synaptic depression in the hippocampus of cancer-bearing rats.

**PRG-1/PP2A interaction were increased by hippocampal injection of FTY720**

In hippocampus, the expression level of PRG-1 was further increased after FTY720 treatment (D39-43, 20 μg once per day) in the BCP rats by immunofluorescence and western blot analysis (Figure 6A-B), indicating the expression of PRG-1 is enhanced by FTY720 in BCP. Since our data so far provided strong evidence for a role of PRG-1 and PP2A in BCP, we assessed direct molecular interaction between both molecules. Using CoIP, we found that PRG-1/PP2A interaction was decreased in BCP rats but reversed by repeatly FTY720 treatments (Figure 6C), suggesting FTY720 relieved BCP and rescued neuron deactivation and synaptic anomalies via PRG-1/PP2A interaction. Furthermore, transcripts for PRG-1 and P2X7 receptor were revealed by quantitative RT-PCR. Quantitative analysis showed that the transcription of PRG-1 and P2X7 receptor mRNA was also increased in the hippocampus of BCP rats with FTY720 treatment (Figure 6D-E). These data suggested that the expression of PRG-1 and P2X7 receptor was specifically increased by transcription step in the BCP + FTY720 rats. Western blot showed the upregulated or silenced expression of PRG-1 and P2X7R induced by virus expression vectors (Figure 6F).

![Figure 6. PRG-1/PP2A interaction were increased by hippocampal injections of FTY720. (A) Images of PRG-1 (red) and P2X7 receptor (green) in the hippocampus from BCP, BCP+FTY720 and BCP+A438079 rats by immunofluorescence on the POD 44 (scale bar = 50 μm). (B) Western blot showed that the expression of PRG-1 and P2X7 receptor was increased in the hippocampus of BCP+FTY720 rats. (C) Co-immunoprecipitation (IP) using a PRG-1 antibody shows PRG-1 and PP2A association. (D-E) Quantitative analysis of RT-qPCR showed that the transcription of PRG-1 and P2X7 receptor mRNA was increased in the hippocampus of BCP+FTY720 rats. β-actin was included as a control. The data are expressed as the mean ± SEM; n = 6; D: Kruskal-Wallis test; E: one-way ANOVA; *P <0.05, **P <0.005, ***P <0.001 compared to the BCP group. (F) Band of western blot showed the expression of PRG-1 and P2X7 receptor induced by virus expression vectors. BCP, bone cancer pain; OE, overexpression; KD, knock down; POD, postoperative day.](http://www.ijbs.com)
PRG-1 relieves pain in BCP rats via P2X7R/PRG-1/PP2A signaling

Here we identified hippocampal P2X7 receptor, PRG-1, PP2A are all involved in bone cancer pain and BCP induced depression, then we planned to determine the upstream and downstream relationship of them. Neither BzATP (D41-44, 100 nM, once per day), a P2X7 receptor agonist or A438079 (D41-44, 1 μg, once per day) could play an analgesic role under PRG-1 overexpression or PRG-1 KD in BCP rats, respectively (Figure 7A), indicating that P2X7 receptor play a role in BCP through PRG-1 and P2X7 receptor is the upstream signal of PRG-1 in BCP. Under PRG-1 KD, FTY720 (D41-44, 20 μg, once per day) remain an analgesic effect (Figure 7A), indicating that PP2A was downstream of PRG-1. Under P2X7R KD, FTY720 (D41-44, 20 μg, once per day) still played analgesic role (Figure 7B), indicating that PP2A was in the downstream of P2X7R. These results further verified that PRG-1 relieves pain in BCP rats via P2X7R/PRG-1/PP2A signaling.

Discussion

Many studies suggests an involvement of PRG-1 in the pathogenesis and/or reparation attempts in neurological disease such as epilepsy [34, 38, 39], neurotrauma, Parkinson’s disease [36], memory impairment [35] and cancer, including tumor progression or metastasis because of its putative target of LPA, a pro-cancerogenous factor [46, 80]. These PRG-1 actions may be dependent of extracellular role in controlling LPA receptor-mediated excitatory synaptic transmission (or synaptic hyperexcitability) [34, 45], or in a cell-autonomous fashion in regulating spinogenesis via intracellular PRG-1/PP2A signaling pathway [35]. In this study we report a new physiological role of PRG-1 for chronic pain and depressive-like behaviors.

We demonstrate that BCP rats showed thermal hyperalgesia, depressive-like behaviors, reduced spine density, mild activation of PRG-1 and P2X7 receptor in hippocampus compared with sham group. But hippocampal PRG-1 and P2X7 receptor play contradictory roles in BCP. PRG-1 overexpression plays a role in alleviating pain and depression-like behaviors, while PRG-1 KD leads to an early-initiated intensified pain and depression, indicating activation of PRG-1 in the hippocampus participates in the analgesic mechanisms and antidepressant effect on bone cancer pain in rats. In order to alleviate the injury caused by bone cancer pain, PRG-1 expression in hippocampus was upregulated for a compensatory protective effect confront with the bone cancer induced pain, in accordance to the compensatory protective effect of PRG-1 on brain injury caused by flurothyl-induced recurrent neonatal seizures [81].

To uncover the analgesic mechanisms of PRG-1 on bone cancer pain in rats, we test for the role of PRG-1/PP2A signaling in mediating bone cancer induced pain. We used established pharmacological tools to stimulate PRG-1/PP2A signaling. Following hippocampal microinjection of FTY720, which serves as an activator of PP2A [76] and PRG-1/PP2A signaling [35], BCP rats showed a significant increase in TWL and MWT with cumulative effect and also rescued sucrose preference of BCP rats. In line with these results, selective inhibition of PP2A by okadaic acid [77] significantly decreased this TWL. These data suggested that PRG-1/PP2A pathway attenuated bone cancer pain and depression-like behaviors in cancer-bearing rats. These data provide evidence for the fact that PRG-1 relieves pain and depressive-like behaviors in rats with bone cancer pain by dendritic spine regulation in hippocampus via PRG-1/PP2A pathway.

In contrast, selective inhibition of P2X7 receptor by antagonist A438079 [78] also significantly
increased TWL and MWT without cumulative effect. Moreover, A438079 were able to rescue sucrose preference of BCP rats. In line with these results, selective enhancer of P2X7 receptor by BzATP [79] significantly decreased this TWL. P2X7 receptor KD also showed analgesic effect in BCP rats, but didn’t change depression-like behavior. These further verified the algogenic effect of hippocampal P2X7 receptor on BCP.

The activation of spinal and supraspinal P2X7 receptors plays a key role in the occurrence and development mechanisms of various kinds of acute or chronic pain [54-56], including neuropathic pain and inflammatory pain [49], while the exact role of P2X7 receptor in BCP still remains controversial. Hansen et al. [58] discovered that P2X7 receptor knockout mice were more susceptible to BCP. Just the other way, Huang et al. [57] demonstrated that the activation of microglial P2X7 receptor in the rostral ventromedial medulla (RVM) is involved in the development of BCP by the mechanism of descending facilitatory via the spinal 5-HT. Li et al. [54] found that activation of the P2X7 receptor in the ventrolateral region of the periaqueductal gray (vlPAG) contributes to the analgesic effect of tramadol on bone cancer pain in rats. In this study, we verified the algogenic role of hippocampal P2X7 receptor on BCP in accordance with Shen et al. [82], who reported that activation of hippocampus P2X7 receptor aggravated neuropathic pain of diabetic rats.

Both PRG-1 and P2X7 receptor in hippocampus are involved in BCP and immunofluorescence revealed partial colocalization with P2X7 receptor of PRG-1. Meanwhile, we confirmed that P2X7 receptor plays a role in BCP through PRG-1, suggesting a possible correlation of PRG-1 and P2X7 receptor to jointly regulate the formation and maintenance of BCP, but there has not been any report on the relationship between P2X7 receptor and PRG-1 in hippocampus in pain modulation. However, immunoprecipitation studies failed to demonstrate a direct interaction between PRG-1 and P2X7 receptor. There could be some intermediary molecules between PRG-1 and P2X7 receptor in BCP regulation.

P2X7 receptor activation induced large numbers of Ca2+ influx activate a variety of downstream cell signal transduction pathways that excite sensory neurons, especially nociceptive neurons, thereby increasing their excitability and resulting in a higher level of pain sensation [59, 61, 62]. Tokumitsu group identified a calmodulin-binding domain in the intracellular C terminus of PRG-1 (at aa 554–588), termed CBD, and suggest PRG-1 regulates excitatory synaptic transmission via PRG-1/CaM binding and controlled by changes in the concentration of intracellular Ca2+ [36]. We previously reported that calmodulin binding domain of PRG-1 within the intracellular C-terminus mediates PP2A holoenzyme interaction. This PRG-1 CBD/PP2A interaction seems to be critical for organization of the adhesome [35]. It is speculated that PP2A and CaM may be competitively bound to the same CBD region of PRG-1 C-terminal, the increase of intracellular Ca2+ changes PRG-1 function by inhibiting PRG-1/PP2A binding, leads to dendrite spine density decrease and bone cancer pain. In order to alleviate the injury caused by bone cancer pain, PRG-1 expression in hippocampus was upregulated for a compensatory protective effect confront with the bone cancer induced pain. If we treated BCP rats with FTY720 or PRG-1 overexpression, PRG-1 and PP2A binding were enhanced, counteract the effect of Ca2+ increase, enabled dendritic spine density recovery, alleviated bone cancer pain and depression. Thus, we hypothesized that a mechanism may exist in hippocampus in BCP rats, that is, P2X7 receptors in BCP rats are activated, and further promote Ca2+ influx, leading to PRG-1 function changing, ultimately inducing PRG-1 activation as a compensatory protective effect (Figure 8). The hypotheses need to be further validated.

Together with the functional and behavioral data, our molecular and morphological studies provide evidence to prove the fact that hippocampal PRG-1 drives a
cell-autonomous signaling pathway involved in the regulation of spine density, and subsequently pain and depression-like behavior control via P2X7R/PRG-1/PP2A pathway, thus providing theoretical basis for a novel analgesia and depression relief strategies targeting PRG-1.

**Abbreviations**

ATP: adenosine triphosphate; BCP: bone cancer pain; BSA: bovine serum albumin; CBD: calmodulin-binding domain; CoIP: Co-immunoprecipitation; DG: dentate gyri; EPSCs: excitatory postsynaptic currents; FST: forced swimming test; HE staining: periaqueductal gray; WB: western blot; WT: wild type.

**Acknowledgements**

This work was supported by the National Natural Science Foundation of China (81960217, 81760214), the Doctoral Scientific Research Startup Fund Project of Zunyi Medical University (F-954), Guizhou Provincial Science and Technology Foundation (QianKeHe JiChu [2017]1214) and the Innovative and Entrepreneurship Training Programme for College Students of Zunyi Medical University (ZYDC2019066, ZYDC2020049).

**Author Contributions**

XL and Z Xiao designed the research; XL, Z Xie, SL and JH performed the research; XL and Z Xie analyzed data; XL wrote the original draft and made the figures; SC and Z Xiao revised the manuscript. All authors contributed to drafting or editing of parts of the manuscript and approved the final version of the manuscript.

**Competing Interests**

The authors have declared that no competing interest exists.

**References**

1. UK CR. Cancer incidence statistics. www.cancerresearchuk.org/health-professional/cancer-statistics/incidence.
2. Mystakidou K, Tsilika E, Parpa E, et al. Exploring the relationships between depression, hopelessness, cognitive status, pain, and spirituality in patients with advanced cancer. Arch Psychiatr Nurs. 2007; 21(5):150-161.
3. Smith HR. Depression in cancer patients: Pathogenesis, implications and treatment. Oncology Letters. 2015; 9(4):1509-1514.
4. Dai J, Ding Z, Zhang J, et al. Minocycline Relieves Depressive-Like Behaviors in Rats With Bone Cancer Pain by Inhibiting Microglia Activation in Hippocampus. Anesth Analg. 2019; 129(6):1735-1741.
5. Pitman A, Suleman S, Hyde N, et al. Depression and anxiety in patients with cancer. BMJ. 2018; 361:k14115.
6. Mantyh PW, Clohisy DR, Koltezmbrug M, et al. Molecular mechanisms of cancer pain. Nat Rev Cancer. 2002; 2(3):201-9.
7. Green CR, Hart-Johnson T, Loeffller DR. Cancer-related chronic pain: examining quality of life in diverse cancer survivors. Cancer. 2011; 117(9):1994-2003.
8. Luger NM, Mac B, Sevick MA, et al. Bone cancer pain: from model to mechanism to therapy. J Pain Symptom Manage. 2005; 29(5 Suppl):S32-46.
9. Ripamonti C, Dickerson ED. Strategies for the treatment of cancer pain in the new millennium. Drugs. 2001; 61(7):955-77.
10. Feller L, Khammissa RAG, Bouckaert M, et al. Pain: Persistent postsurgery and bone cancer-related pain. J Int Med Res. 2019; 47(2):528-543.
11. Schmidt BL, Hamamoto DT, Simone DA, et al. Mechanism of cancer pain. Mol Interv. 2010; 10(3):164-78.
12. Dies PD, Leston JS. Oral cancer pain. Oral Oncol. 2010; 46(6):448-51.
13. Falk S, Dickerson AH. Pain and nociception: mechanisms of cancer-induced bone pain. J Clin Oncol. 2014; 32(16):1647-54.
14. Sabino MA, Mantyh PW. Pathophysiology of bone cancer pain. J Support Oncol. 2005; 3(1):15-24.
15. Vasic V, Schmidt MH. Resilience and Vulnerability to Pain and Inflammation in the Hippocampus. Int J Mol Sci. 2017; 18(4).
16. Liu MG, Chen J. Roles of the hippocampal formation in pain information processing. J Neuroscience Bulletin. 2009; 25(2):237-266.
17. Miladinovic T, Sharma M, Phan A, et al. Activation of hippocampal microglia in a murine model of cancer-induced pain. Journal of Pain Research. 2019; 12.
18. Petrlik D, Esch AJ. Depression and Hippocampal Neurogenesis: A Road to Remission? Science. 2012.
19. Seifert F, Mihlfner C. Central mechanisms of experimental and chronic neuropathic pain: Findings from functional imaging studies. J Cellular Molecular Life Sciences. 2009; 66(3):375.
20. Thompson SJ, Millecamps M, Aliaga A, et al. Metabolic brain activity suggestive of persistent pain in a rat model of neuropathic pain. J Neuroimaging. 2014; 91:344-352.
21. Coppieters I, De Pauw R, Caeyenberghs K, et al. Differences in white matter structure and cortical thickness between patients with traumatic and idiopathic chronic neck pain: Associations with cognition and pain modulation? Hum Brain Mapp. 2018; 39(4):1721-1742.
22. Vachon-Presseau E, Berger SE, Abdullah TB, et al. Identification of traits and functional connectivity-based neurotraits of chronic pain. J PLOS Biology. 2019; 17.
23. Yuan J, Yu T, Zhang MZ. Research progress of resting-state functional connectivity modulation? Hum Brain Mapp. 2018; 39(4):1721-1742.
24. Vachon-Presseau E, Berger SE, Abdullah TB, et al. Identification of traits and functional connectivity-based neurotraits of chronic pain. J PLOS Biology. 2019; 17.
25. Mercenier A, Zingg S, van Uden H, et al. Hypersensitivity of disability following nerve injury. J Pain Symptom Manage. 2005; 29(5 Suppl):S32-46.
26. Xiong B, Zhang W, Zhang L, et al. Hippocampal glutamatergic synapses impairment mediated novel-object recognition dysfunction of neuropathic pain in rats. J Pain. 2020;1.
27. Mutso AA, Radzick D, Baliki MN, et al. Abnormalities in hippocampal functioning with persistent pain. J Neurosci. 2012; 32(17):5747-56.
28. Terada M, Kuzumaki N, Hareyama N, et al. Suppression of enriched environment-induced neurogenesis in a rodent model of neuropathic pain. J Neuroscience Letters. 2008; 440(3):314-318.

29. Dellarole A, Morton P, Brambilla R, et al. Neuropathic pain-induced depressive-like behavior and hippocampal neurogenesis and plasticity are dependent on TNFRI signaling. J Brain Behavior Immunity. 2014; 41:65-81.

30. Wei X, Centeno MV, Ren W, et al. Activation of the dorsal, but not ventral, hippocampus relieves neuropathic pain in rodents. J Pain. 2021; Publish Ahead of Print.

31. McKeema JE, Melzack R. Analgesia produced by lidocaine microinjection into the dentate gyrus. J Pain Res. 1992; 4(1):105.

32. Braunau AU, Savaskan NE, Kuhn H, et al. A new phospholipid phosphatase, PRG-1, is involved in axon growth and regenerative sprouting. Nat Neurosci. 2005; 8(6):572-8.

33. Strauss U, Braunau AU. Current views on regulation and function of plasticity-related genes (PRGs/LPPRs) in the brain. Biochim Biophys Acta. 2013; 1831(1):133-8.

34. Trimbuch T, Bedd P, Vogt J, et al. Synaptic PRG-1 regulates excitatory transmission via lipid phosphate-mediated signaling. Cell. 2009; 138(6):1225-27.

35. Liu X, Huai J, Endle H, et al. PRG-1 Regulates Synaptic Plasticity via Intracellular PP2A/beta1-Integrin Signaling. Dev Cell. 2016; 38(3):275-90.

36. Tokumitsu H, Hatanou N, Tsuchiya M, et al. Identification and characterization of PRG-1 as a neuronal calmodulin-binding protein. Biochem J. 2014; 463(1):181-91.

37. Moran LB, Duke DC, Deprez M, et al. Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson's disease. Neurogenetics. 2006; 7(1):1-11.

38. Vogt J, Kirischuk S, Unichenko P, et al. Synaptic Phospholipid Signaling Modules Axon Outgrowth via Glutamate-dependent Ca2+-mediated Molecular Pathways. Cereb Cortex. 2017; 27(1):131-145.

39. Ni H, Jiang YW, Tao LY, et al. ZnT-1, ZnT-3, CaMK II, PRG-1 expressions in rat skeletal muscle tissue. Int J Molecular Science. 2021; 17(12):4019.

40. Li P, Zhang Q, Xiao Z, et al. Activation of the P2X7 receptor in midbrain periaqueductal gray participates in the analgesic effect of tramadol in bone cancer pain rats. Mol Pain. 2018; 14:1-14.

41. Yang J, Park KS, Yoon JJ, et al. Anti-alldynic effect of intrathecally prepared Acoumtum jaluense is associated with the inhibition of microglial activation and P2X7 receptor expression in spinal cord. BMC Complement Altern Med. 2016; 16:214.

42. Xie J, Liu S, Wu B, et al. The protective effect of resveratrol in the transmission of neuropathic pain mediated by the P2X7 receptor in the dorsal root ganglia. Neurochem Int. 2017; 103:24-35.

43. Huang ZX, Lu ZJ, Ma WQ, et al. Involvement of RVM-expressed P2X7 receptor in bone cancer pain: mechanism of descending facilitation. Pain. 2014; 155(4):783-791.

44. Hansen RE, Nielsen CK, Nasser A, et al. P2X7 receptor-deficient mice are susceptible to bone cancer pain. Pain. 2011; 152(6):1766-1776.

45. Burnstock G, Di Virgilio F. Purinergic signalling and cancer. Purinergic Signal. 2013; 9(4):491-540.

46. Sorge RE, Trang T, Dorfman R, et al. Genetically determined P2X7 receptor pore formation regulates variability in chronic pain sensitivity. Nat Med. 2012; 18(4):595-9.

47. Nobles M, Monaldi I, Alloisio S, et al. ATIP-induced, sustained calcium signalling in cultured rat cortical astrocytes: evidence for a non-capacitative, P2X7-like-mediated calcium entry. FEBS Lett. 2003; 538(1-3):71-6.

48. Sperlagh B, Vizi ES, Wirkner K, et al. P2X7 receptors in the nervous system. Prog Neurobiol. 2006; 78(6):327-46.

49. Gare M, Silva HM, Lafaille JJ, et al. P2X7 receptor inhibition ameliorates dermal spine pathology and social behavioral deficits in Rett syndrome mice. Nature Communications. 2020; 11(1).

50. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain. 1983; 16(2):109-110.

51. Shenoy PA, Kuo A, Vetter I, et al. The Walker 256 Breast Cancer Cell-Induced Bone Pain Model in Rats. Frontiers in Pharmacology. 2016; 7.

52. Liu PX, Zhu RY, Liu CY, et al. Evaluation of Decalcification Techniques for Rat Femurs Using HE and Immunohistochemical Staining. Biomed Research International. 2017; 2017.

53. Luo T, Yu S, Cai S, et al. Parabuchial Neurons Promote Behavior and Electrocencephalographic Arousal From General Anesthesia. Front Mol Neurosci. 2018; 11:420.

54. Paxinos G, Watson C. “The Rat Brain in Stereotaxic Coordinates,” 6th Edition. 2007. Cambridge: Academic Press.

55. Rivlin AS, Tator CH. Objective clinical assessment of motor function after experimental spinal cord injury in the rat. J Neurosurgery. 1977; 47(4):577-81.

56. Hargreaves K DR, Brown F, Flores C and Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain. 1988; 32:77-88.

57. Vivancos G, Verri W, Cunha T, et al. An electronic pressure-meter-nociception paw test for rats. Braz J Med Biol Res. 2004; 37(3):391-9.

58. Huang L, Wan Y, Dang Z, et al. Hypoxic preconditioning ameliorated neuronal injury after middle cerebral artery occlusion by promoting neurogenesis. Brain Behav. Neurosci. 2021; 2:1-10.

59. Zuo D, Lin L, Liu Y, et al. Bicalutamid Attenuates Ketamine-Induced Neurotoxicity in the Developing Rats: Involvement of P38/PI3K/Akt and CREB/BDNF/Blk-2 Pathways. J Neurotoxicity Research. 2016; 30(2):139-172.

60. Theer P, Monge K, coup M. PSFj know your fluorescence microscope. Int Rev Cytol. 2014; 11(10):981-2.

61. Zhao M, Wang W, Jiang Z, et al. Long-Term Effect of Post-traumatic Stress in Adolescence on Dendrite Development and H3K9me2/BDNF Expression in Male Rat Hippocampus and Prefrontal Cortex. Front Cell Dev Biol. 2020; 8:682.

62. Pernotti D, Neviani P. Protein phosphatase 2A: a target for anticancer therapy. Lancet Oncol. 2013; 14(6):229-38.

63. Takai Y, Kaiuchi K, Kikuchi A, et al. Small GTP-binding proteins. Int Rev Cytol. 1992; 133:187-230.

64. Sekar P, Huang DY, Hsieh SL, et al. AMPK-dependent and independent actions of P2X7 in regulation of mitochondrial and lysosomal functions in microglia. Cell Communication and Signaling. 2018; 16.

65. Surprenant A, Rassendren F, Kawashima E, et al. The cytolytic P2Z receptor pore formation regulates variability in chronic pain sensitivity. Nat Med. 2012; 18(4):595-9.

66. Murph M, Tanaka T, Pang J, et al. Liquid chromatography mass spectrometry for quantifying plasma lysophospholipids: potential biomarkers for cancer diagnosis. Methods Enzymol. 2007; 433:1-25.

67. Ni H, Jiang YW, Xiao ZJ, et al. Dynamic pattern of gene expression of ZnT-1, ZnT-3 and PRG-1 in rat brain following fluoroethyl-induced recurrent neonatal seizures. Toxicol Lett. 2010; 194(3):86-93.

http://www.ijbs.com
82. Shen Y, Guan S, Ge H X, et al. Effects of palmatine on rats with comorbidity of diabetic neuropathic pain and depression. Brain Research Bulletin. 2018; 139:56-66.